The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | Impact of checkpoint inhibitor-based salvage regimens prior to alloSCT in R/R cHL
Sanjal Desai, MBBS, University of Minnesota, Minneapolis, MN, discusses a study assessing the impact of checkpoint inhibitor (CPI) or brentuximab vedotin (BV)-based salvage regimens prior to allogeneic stem cell transplantation (alloSCT) in patients with classic Hodgkin lymphoma (cHL) who relapse after frontline chemoimmunotherapy. Dr Desai shares the impact of these treatments on progression-free survival (PFS) post-transplant. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
